Literature DB >> 29465789

A real-world experience with augmentation enterocystoplasty-High patient satisfaction with high complication rates.

Shu-Yu Wu1, Hann-Chorng Kuo1.   

Abstract

AIMS: To investigate the real treatment outcomes after augmentation enterocystoplasty (AE) of patients with refractory neurogenic lower urinary tract dysfunction.
METHODS: Retrospective follow-up in a single center. The videourodynamic data, renal function, incontinence grade, voiding pattern and management, clinical outcome, and complications were evaluated.
RESULTS: Seventy-nine patients (62 men and 17 women) were included. The mean age at operation was 39.4 ± 11.6 years and the mean follow-up period was 128.4 ± 85.2 months. At follow-up, 5 (6.7%) patients had spontaneous voiding, 60 (80%) had to perform clean intermittent catheterization, and 10 (13.3%) chose to keep the indwelling catheter. The catheter-dependent rate was 93.3% and complete catheter-dependent rate was 76%. Renal function of the patients did not appear to be significantly different after AE. Three patients developed end-stage renal disease. The incontinence grade showed significant improvement (P = 0.000). Among all the patients, 41.8% experienced recurrent urinary tract infections requiring medical treatment and 21.5% suffered from chronic diarrhea. Overall, 45.6% of the patients experienced complications requiring surgical interventions, most of which were stones. Life-threatening complications like bowel obstruction and bladder cancer were also noted. Three patients even expired within one year postoperatively. The majority (86.8%) of patients reported moderate to excellent satisfaction with the outcome of AE.
CONCLUSIONS: AE is a procedure with long-term durability and high rates of patient satisfaction. However, several bothersome complications affecting life quality may occur. Both patients and doctors thus need to consider possible outcomes carefully before the operation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  augmentation enterocystoplasty; lower urinary tract dysfunction; neurogenic bladder

Mesh:

Year:  2018        PMID: 29465789     DOI: 10.1002/nau.23339

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  4 in total

Review 1.  Augmentation cystoplasty in the patient with neurogenic bladder.

Authors:  Philip J Cheng; Jeremy B Myers
Journal:  World J Urol       Date:  2019-09-11       Impact factor: 4.226

2.  Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.

Authors:  Yuan-Hong Jiang; Sheng-Fu Chen; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2020-12-31       Impact factor: 2.835

3.  Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury.

Authors:  Sheng-Fu Chen; Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2022-01-03       Impact factor: 4.546

4.  Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.

Authors:  Chih-Chieh Lin; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2022-01-10       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.